Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | ITGAV | P06756 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630004 | 1.00 | POLB (0.53) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL8269061 | 1.00 | POLB (0.53) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL629759 | 0.91 | KCNQ1 (0.56) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL1383477 | 0.91 | KCNQ1 (0.56) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL630614 | 0.90 | POLB (0.44) | POLBKCNQ1HCRTR1HCRTR2BDKRB1 | |
| SCHEMBL1383043 | 0.89 | LMNA (0.53) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL630316 | 0.89 | LMNA (0.53) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL13206969 | 0.89 | LMNA (0.53) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL13206964 | 0.89 | POLB (0.51) | POLBITGB1ITGA5ITGA4KCNQ1 | |
| SCHEMBL1383068 | 0.89 | POLB (0.51) | POLBITGB1ITGA5ITGA4KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | POLB 4105/4885ITGB1 3840/4885ITGA5 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.